66.30.Z - Fund management activities
64.30.Z - Trusts, funds and similar financial entities
70.22.Z - Business and other management consultancy activities
71.20.B - Other technical testing and analysis
72.11.Z - Research and experimental development on biotechnology
72.19.Z - Other research and experimental development on natural sciences and engineering
72.20.Z - Research and experimental development on social sciences and humanities
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
2020 | 2021 | 2022 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | -1 | -2,7 | -0,5 | 83,1 |
EBITDA | -0 | -0,3 | -0,1 | 71,7 |
Short time liabilities | 0 | 0 | 0 | -30,2 |
Equity capital | 5,2 | 2,4 | 1,9 | -19,2 |
Operating profit (EBIT) | -0 | -0,3 | -0,1 | 70,4 |
Assets | 5,2 | 2,4 | 1,9 | -19,3 |
Net profit (loss) | -1 | -2,8 | -0,5 | 83,7 |
Cash | 0 | 0,3 | 0,1 | -71,2 |
Net income from sale | 0 | 0 | 0 | 0 |
Liabilities and provisions for liabilities | 0 | 0 | 0 | -30,2 |
Working assets | 0,2 | 0,3 | 0,2 | -42,9 |
Depreciation | 0 | 0 | 0 | -∞ |
% | % | % | p.p. | |
Profitability of capital | -19,6 | -117,7 | -23,8 | 93,9 |
Equity capital to total assets | 99,7 | 99,4 | 99,5 | 0,1 |
Gross profit margin | -27 204,3 | |||
EBITDA Margin | -59,3 | |||
Days | Days | Days | Days | |
Short term commitment turnover cycle | 1650 | 2 147 483 648 | 2 147 483 648 | 0 |
Current financial liquidity indicator | 13.070647239685059 | 18.748668670654297 | 15.33976936340332 | -3,4 |
Net dept to EBITDA | -0.054393358528614044 | 0.9295369982719421 | 0.9213824272155762 | 0 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane